JP5956448B2 - 医薬組成物 - Google Patents

医薬組成物 Download PDF

Info

Publication number
JP5956448B2
JP5956448B2 JP2013530177A JP2013530177A JP5956448B2 JP 5956448 B2 JP5956448 B2 JP 5956448B2 JP 2013530177 A JP2013530177 A JP 2013530177A JP 2013530177 A JP2013530177 A JP 2013530177A JP 5956448 B2 JP5956448 B2 JP 5956448B2
Authority
JP
Japan
Prior art keywords
methyl
hydrogen
pharmaceutically acceptable
cancer
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013530177A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538825A (ja
JP2013538825A5 (enExample
Inventor
スパイヴィー，マーク
サトー，タカシ
カールソン，ジョナサン・エリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2013538825A publication Critical patent/JP2013538825A/ja
Publication of JP2013538825A5 publication Critical patent/JP2013538825A5/ja
Application granted granted Critical
Publication of JP5956448B2 publication Critical patent/JP5956448B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2013530177A 2010-09-21 2011-09-12 医薬組成物 Active JP5956448B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38478110P 2010-09-21 2010-09-21
US61/384,781 2010-09-21
PCT/US2011/051163 WO2012039972A1 (en) 2010-09-21 2011-09-12 Pharmaceutical composition

Publications (3)

Publication Number Publication Date
JP2013538825A JP2013538825A (ja) 2013-10-17
JP2013538825A5 JP2013538825A5 (enExample) 2014-10-30
JP5956448B2 true JP5956448B2 (ja) 2016-07-27

Family

ID=44674894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013530177A Active JP5956448B2 (ja) 2010-09-21 2011-09-12 医薬組成物

Country Status (31)

Country Link
US (2) US8686018B2 (enExample)
EP (2) EP3061751A1 (enExample)
JP (1) JP5956448B2 (enExample)
KR (1) KR101911105B1 (enExample)
CN (1) CN103097358B (enExample)
AU (1) AU2011305872B2 (enExample)
BR (1) BR112013002484B1 (enExample)
CA (1) CA2806121C (enExample)
CL (1) CL2013000675A1 (enExample)
CY (1) CY1118680T1 (enExample)
DK (1) DK2619182T3 (enExample)
ES (1) ES2610185T3 (enExample)
HR (1) HRP20170042T1 (enExample)
HU (1) HUE031408T2 (enExample)
IL (1) IL224288A (enExample)
LT (1) LT2619182T (enExample)
ME (1) ME02575B (enExample)
MX (1) MX2013003162A (enExample)
MY (1) MY162146A (enExample)
NZ (1) NZ606629A (enExample)
PE (1) PE20131343A1 (enExample)
PH (1) PH12013500467A1 (enExample)
PL (1) PL2619182T3 (enExample)
PT (1) PT2619182T (enExample)
RS (1) RS55566B1 (enExample)
RU (1) RU2606510C2 (enExample)
SG (1) SG188188A1 (enExample)
SI (1) SI2619182T1 (enExample)
SM (2) SMT201700008T1 (enExample)
UA (1) UA113499C2 (enExample)
WO (1) WO2012039972A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
WO2014200075A1 (ja) 2013-06-12 2014-12-18 科研製薬株式会社 ４－アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬
TW201623277A (zh) * 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
KR102535283B1 (ko) * 2014-05-23 2023-05-22 에자이 알앤드디 매니지먼트 가부시키가이샤 암의 치료를 위한 조합 요법
TWI730959B (zh) 2015-05-19 2021-06-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
CA2993312A1 (en) 2015-07-23 2017-01-26 Takeda Pharmaceutical Company Limited 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
WO2017066633A1 (en) 2015-10-16 2017-04-20 Eisai R&D Management Co., Ltd. Ep4 antagonists
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
ES2896476T3 (es) 2017-05-18 2022-02-24 Idorsia Pharmaceuticals Ltd Derivados de pirimidina
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
HRP20211533T1 (hr) 2017-05-18 2022-01-07 Idorsia Pharmaceuticals Ltd Derivati fenila kao modulatori receptora pge2
TWI768043B (zh) 2017-05-18 2022-06-21 瑞士商愛杜西亞製藥有限公司 N-取代吲哚衍生物
CN108929281B (zh) * 2017-05-27 2021-12-24 华东师范大学 三氮唑类化合物及其合成方法和应用
AU2019214193B2 (en) * 2018-02-05 2022-06-16 Foshan Ionova Biotherapeutics Co., Inc. Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases
US20230125494A1 (en) * 2020-03-04 2023-04-27 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Synthesis of novel ep4 antagonist and use in cancer and inflammation
WO2022037601A1 (zh) * 2020-08-18 2022-02-24 武汉人福创新药物研发中心有限公司 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在制备治疗癌症和炎症药物中的用途
KR20230107228A (ko) 2020-11-13 2023-07-14 오노 야꾸힝 고교 가부시키가이샤 Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료
TWI877433B (zh) 2020-11-30 2025-03-21 大陸商杭州阿諾生物醫藥科技有限公司 用於治療ｐｉｋ３ｃａ突變癌症的組合療法
CN116801879B (zh) * 2021-01-28 2025-09-26 深圳众格生物科技有限公司 吡唑酰胺衍生物及其制备方法和应用
CA3230557A1 (en) * 2021-09-03 2023-03-09 Xuejun Zhang Ep4 antagonist compound as well as salt, polymorph, and use thereof
CN115364222A (zh) * 2021-09-09 2022-11-22 首都医科大学附属北京地坛医院 Ep4受体抑制剂治疗肝纤维化的应用
CN118414328A (zh) 2021-12-23 2024-07-30 卫材R&D管理有限公司 Ep4拮抗剂的结晶盐形式
JP2024544423A (ja) * 2021-12-30 2024-11-29 杭州阿諾生物医薬科技有限公司 固体医薬組成物
WO2024027599A1 (zh) * 2022-08-04 2024-02-08 杭州阿诺生物医药科技有限公司 预测直肠癌对an0025联合放疗/放化疗(rt/crt)治疗敏感性的生物标志物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0421671A (ja) * 1990-05-16 1992-01-24 Mitsubishi Kasei Corp ４―ピラゾールカルボキサミド類およびこれを有効成分とする殺虫、殺ダニ剤
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US6211197B1 (en) * 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
US7119108B1 (en) 1999-10-18 2006-10-10 University Of Connecticut Pyrazole derivatives as cannabinoid receptor antagonists
US7393842B2 (en) 2001-08-31 2008-07-01 University Of Connecticut Pyrazole analogs acting on cannabinoid receptors
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
TW591020B (en) 2001-06-20 2004-06-11 Wyeth Corp 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
WO2004037212A2 (en) 2002-10-24 2004-05-06 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
FR2847160A1 (fr) 2002-11-20 2004-05-21 Oreal Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
CN1832928B (zh) * 2003-06-26 2012-07-04 诺瓦提斯公司 以5元杂环为基础的p38激酶抑制剂
EP1663979B1 (en) 2003-09-03 2013-10-09 RaQualia Pharma Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
GT200500013A (es) 2004-01-23 2005-08-10 Amidas herbicidas
AU2005238292A1 (en) * 2004-05-04 2005-11-10 Pfizer Inc. Ortho substituted aryl or heteroaryl amide compounds
AP2006003785A0 (en) * 2004-05-04 2006-10-31 Pfizer Substituted methylaryl or heteroaryl amide compounds
TW200716576A (en) 2005-06-07 2007-05-01 Shionogi & Co Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US20090131470A1 (en) * 2005-06-11 2009-05-21 Vernalis R & D Limited Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders
CN101273013B (zh) * 2005-09-27 2013-06-12 盐野义制药株式会社 具有pgd2受体拮抗活性的磺酰胺衍生物
KR101024227B1 (ko) 2005-11-21 2011-03-29 시오노기세이야쿠가부시키가이샤 11-β-히드록시스테로이드 탈수소효소 제 Ⅰ 형에 대한저해 활성을 갖는 헤테로시클릭 화합물
US7994204B2 (en) * 2006-02-06 2011-08-09 Taisho Pharmaceutical Co., Ltd Binding inhibitor of sphingosine-1-phosphate
WO2007143825A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
CN101541778B (zh) 2006-08-11 2014-10-08 默克加拿大有限公司 作为ep4受体配体的噻吩甲酰胺衍生物
CA2672631A1 (en) 2006-12-15 2008-06-19 Glaxo Group Limited Benzamide derivatives as ep4 receptor agonists
EP2114877B1 (en) 2007-02-26 2012-12-26 Merck Canada Inc. Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
US7560936B1 (en) 2007-04-24 2009-07-14 Integrated Device Technology, Inc. Method and apparatus for ground bounce and power supply bounce detection
WO2008152138A2 (de) 2007-06-15 2008-12-18 Basf Se Verfahren zur herstellung difluormethylsubstituierter pyrazolverbindungen
WO2009005076A1 (ja) * 2007-07-03 2009-01-08 Astellas Pharma Inc. アミド化合物
JP2010533736A (ja) * 2007-07-19 2010-10-28 ハー・ルンドベック・アクチエゼルスカベット ５員複素環アミドおよび関連化合物
CL2008002241A1 (es) 2007-07-31 2009-12-28 Bayer Cropscience Sa Compuestos derivados de (hetero)aril-metilen-n-cicloalquil carboxamida condensados de 6 elementos con n-sustituido; composicion funguicida que comprende uno de dichos compuestos; y metodo para el control hongos fitopatogenos de cultivos agricolas.
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
CA2722811C (en) * 2008-05-06 2016-07-05 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
PL2565191T3 (pl) * 2008-05-14 2015-03-31 Astellas Pharma Inc Pochodne kwasu 4-(indol-7-ilokarbonyloaminometylo)cykloheksanokarboksylowego jako antagoniści receptora EP4 użyteczni do leczenia przewlekłej niewydolności nerek lub nefropatii cukrzycowej
UA100291C2 (uk) 2008-08-01 2012-12-10 Байєр Кропсайнс Аг Фунгіцидні похідні n-циклоалкіл-n-біфенілметилкарбоксаміду
CA2733247C (en) * 2008-08-14 2018-04-03 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
WO2010034110A1 (en) 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists

Also Published As

Publication number Publication date
DK2619182T3 (en) 2017-01-30
MX2013003162A (es) 2013-05-06
PE20131343A1 (es) 2013-11-18
EP2619182B1 (en) 2016-11-09
CL2013000675A1 (es) 2013-07-05
US9000024B2 (en) 2015-04-07
WO2012039972A1 (en) 2012-03-29
PH12013500467A1 (en) 2013-04-29
CN103097358B (zh) 2015-04-08
RU2606510C2 (ru) 2017-01-10
RS55566B1 (sr) 2017-05-31
HRP20170042T1 (hr) 2017-03-10
SI2619182T1 (sl) 2017-03-31
NZ606629A (en) 2015-03-27
CA2806121C (en) 2018-10-09
IL224288A (en) 2015-02-26
US8686018B2 (en) 2014-04-01
RU2013118209A (ru) 2014-10-27
BR112013002484B1 (pt) 2021-10-13
US20130237578A1 (en) 2013-09-12
AU2011305872B2 (en) 2015-03-26
PT2619182T (pt) 2017-01-17
MY162146A (en) 2017-05-31
ME02575B (me) 2017-06-20
SG188188A1 (en) 2013-04-30
UA113499C2 (xx) 2017-02-10
CN103097358A (zh) 2013-05-08
KR101911105B1 (ko) 2018-10-23
HUE031408T2 (en) 2017-07-28
CA2806121A1 (en) 2012-03-29
CY1118680T1 (el) 2017-07-12
JP2013538825A (ja) 2013-10-17
ES2610185T3 (es) 2017-04-26
US20140155452A1 (en) 2014-06-05
SMT201700008B (it) 2017-03-08
LT2619182T (lt) 2017-01-25
EP3061751A1 (en) 2016-08-31
BR112013002484A2 (pt) 2016-05-31
KR20130099008A (ko) 2013-09-05
PL2619182T3 (pl) 2017-03-31
EP2619182A1 (en) 2013-07-31
SMT201700008T1 (it) 2017-03-08
AU2011305872A1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
JP5956448B2 (ja) 医薬組成物
RU2627268C2 (ru) Аза-арил-1Н-пиразол-1-ил-сульфонамиды
KR101593237B1 (ko) 5-원 헤테로시클릭 아미드 및 관련 화합물
WO2012103071A2 (en) Compounds and compositions
KR101589332B1 (ko) ２ｈ-크로멘 화합물 및 그의 유도체
JP4698681B2 (ja) アミノピリミジン類の化合物及びその塩の調製方法と薬物の用途
KR102212981B1 (ko) 4-알키닐이미다졸 유도체 및 그것을 유효 성분으로서 함유하는 의약
JP2008526887A (ja) カンナビノイド受容体に作用する新規なヘテロピロール類似体
WO2007037534A1 (ja) ２－へテロアリール置換インドール誘導体
KR20070116633A (ko) 피지디2 길항제 활성을 갖는 1-아세틱 애시드-인돌 유도체
CN101636385B (zh) 作为ep4受体拮抗剂的萘和喹啉磺酰脲衍生物
CA2953472C (en) Halogen-substituted heterocyclic compound salt
CN108929281B (zh) 三氮唑类化合物及其合成方法和应用
KR20090016504A (ko) 선택적 칸나비노이드 ｃｂ1 수용체 길항제로서의 황 함유 피라졸 유도체
JP2022549601A (ja) ヘテロアリール血漿カリクレインインヒビター
HK1181765A (en) Pharmaceutical composition
HK1181765B (en) Pharmaceutical composition
US20240390371A1 (en) Heteroaryl and heterocyclic compounds for treating acute inflammation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140910

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160331

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160519

R155 Notification before disposition of declining of application

Free format text: JAPANESE INTERMEDIATE CODE: R155

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160616

R150 Certificate of patent or registration of utility model

Ref document number: 5956448

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250